Chondropeptix Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Early Stage VC

  • Investors
  • 4

Chondropeptix General Information

Description

Operator of a biotechnology company intended to treat cartilage injuries and defects of patients. The company specializes in the research and development of peptide-based drugs to stimulate cartilage regeneration in joints, enabling patients to efficiently recover from cartilage defects without any surgery.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Oxfordlaan 70
  • 6229 EV Maastricht
  • Netherlands
+31 06
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • Oxfordlaan 70
  • 6229 EV Maastricht
  • Netherlands
+31 06

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Chondropeptix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC 01-Nov-2022 Completed Generating Revenue
2. Early Stage VC 05-Jul-2019 Completed Startup
1. University Spin-Out 01-Jan-2018 Completed Startup
To view Chondropeptix’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Chondropeptix Patents

Chondropeptix Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3442559-B1 Bmp-7 derived peptides for use in a method of the treatment or prevention of osteoarthritis Active 13-Apr-2016
EP-3442559-C0 Bmp-7 derived peptides for use in a method of the treatment or prevention of osteoarthritis Active 13-Apr-2016
ES-2837003-T3 Bmp-7 derived peptides for use in the treatment of osteoarthritis Active 13-Apr-2016
EP-3442558-B1 Bmp-7 derived peptides for use in the treatment of osteoarthritis. Active 13-Apr-2016
EP-3442559-A1 Method for the treatment or prevention of osteoarthritis Active 13-Apr-2016 A61K38/1875
To view Chondropeptix’s complete patent history, request access »

Chondropeptix Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Particon PE/Buyout Minority
Limburg Business Development Fund Venture Capital Minority
ReumaNederland Corporation Minority
Maastricht University University Minority
To view Chondropeptix’s complete investors history, request access »

Chondropeptix FAQs

  • When was Chondropeptix founded?

    Chondropeptix was founded in 2018.

  • Where is Chondropeptix headquartered?

    Chondropeptix is headquartered in Maastricht, Netherlands.

  • What industry is Chondropeptix in?

    Chondropeptix’s primary industry is Drug Discovery.

  • Is Chondropeptix a private or public company?

    Chondropeptix is a Private company.

  • What is Chondropeptix’s current revenue?

    The current revenue for Chondropeptix is .

  • How much funding has Chondropeptix raised over time?

    Chondropeptix has raised $1.1M.

  • Who are Chondropeptix’s investors?

    Particon, Limburg Business Development Fund, ReumaNederland, and Maastricht University have invested in Chondropeptix.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process